Radioimmunotherapy for B-cell non-hodgkin lymphomas.

摘要: BACKGROUND Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin lymphomas (NHL), in both up-front relapsed/refractory settings. Two approved agents (90Y-ibritumomab tiuxetan 131I-tositumomab) are available the United States. Both target CD20 similar clinical outcomes but unique considerations radiation precautions due to use of varying radioisotopes. METHODS This paper reviews evidence these RIT examines recently published ongoing trials potential novel indications aggressive NHL. RESULTS A pretreatment biodistribution evaluation required before administering 90Y-ibritumomab dose has been removed, which once limited its usage. The applications include NHL, diffuse large lymphoma, lymphoma front-line setting, mantle cell lymphoma. Multiple preclinical development, addition radiosensitizers or external-beam radiotherapy may act synergy lymphomas. risk treatment-related myelodysplastic syndrome does not appear be higher treated over those receiving chemotherapy alone. CONCLUSIONS safe, effective, significantly underutilized therapy many studies have demonstrated efficacy 131I-tositumomab Continued research establish other subtypes warranted.